BeyondSpring Presents Novel Trial Design for DUBLIN-3 Study BPI-2358-103 at ESMO Congress 2019

NEXT STORY
PDS Biotechnology Prioritizes Development of PDS0101 in Advanced Cancers Following Promising Phase 1 Clinical Outcome Data
PREV STORY
Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Chimerix Announces First Quarter 2018 Financial Results

- Landmark AdVance Study Demonstrates Strong Correlation Between Adenovirus Burden and Mortality Risk - - ...

author_avatar
NASDAQ Market News

Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong

ZEJULA is the first and only PARP inhibitor approved in Hong Kong for the ...

author_avatar
NASDAQ Market News

Aptevo Therapeutics Receives $20 Million Payment From Emergent BioSolutions

SEATTLE, Jan. 13, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company ...

author_avatar
NASDAQ Market News